NASDAQ
17.07.26 | 21:59
2,105 US-Dollar
+1,69 % +0,035
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 30.06. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 3 | GlobeNewswire (USA) | ||
| 30.06. | ALX Oncology names Scott Garland chairman, adds general counsel | 1 | Investing.com | ||
| 30.06. | ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel | 2 | GlobeNewswire (USA) | ||
| 26.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 3 | SEC Filings | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 11.06. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Earnings Call: ALX Oncology übertrifft Gewinnprognose für Q1 2026 | 1 | Investing.com Deutsch | ||
| 09.05. | Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology: 100 % Ansprechrate in Studie bestätigt CD47-Strategie | 6 | Investing.com Deutsch | ||
| 08.05. | ALX Oncology Q1 2026 slides: 100% response validates CD47 strategy | 3 | Investing.com | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.17 beats by $0.02 | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | 675 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 07.05. | ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression | 238 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the... ► Artikel lesen | |
| 17.04. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 2 | GlobeNewswire (USA) | ||
| 13.04. | ALX Oncology names Jeff Knight as chief development officer | 1 | Investing.com | ||
| 13.04. | ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer | 262 | GlobeNewswire (Europe) | - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13... ► Artikel lesen | |
| 13.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Wells Fargo initiates ALX Oncology stock with overweight rating | 6 | Investing.com | ||
| 10.03. | Rüstungs-Rallye nach Iran-Angriff: Rheinmetall, Palantir, DroneShield und Harvest Technology im Fokus der Anleger | Small- & Micro Cap Investment |
1 2 3 Weiter >>
44 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,440 | -0,64 % | Evotec senkt Jahresprognose deutlich | Evotec hat nach vorläufigen Zahlen für das erste Halbjahr 2026 den Ausblick für das Gesamtjahr deutlich nach unten korrigiert. Sowohl die Umsatz- als auch die Ergebnisprognose wurden erheblich reduziert.... ► Artikel lesen | |
| MODERNA | 54,08 | -2,03 % | Moderna-Aktie mit -11% - Einstieg nach der Korrektur? | Die Moderna-Aktie hat nach ihrer beeindruckenden Rallye zuletzt einen Dämpfer hinnehmen müssen und am gestrigen Handelstag rund -11% an Wert verloren. Damit rückt die Aktie nach dem starken Kursanstieg... ► Artikel lesen | |
| NOVAVAX | 7,130 | -0,97 % | Novavax, Inc.: Novavax Reports First Quarter 2026 Financial Results and Operational Highlights | Total revenue of $140 million in the first quarter of 2026
Pfizer agreement announced in January for non-exclusive license to utilize Matrix-M® in two infectious... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 41,765 | -1,66 % | CRISPR Therapeutics AG: CRISPR Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results | ZUG, Switzerland and BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the first quarter ended March 31, 2026. "The first quarter reflected... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,971 | -1,32 % | INOVIO Pharmaceuticals, Inc.: Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China | Results provide important clinical evidence to support ApolloBio's future regulatory submission in China of VGX-3100, INOVIO's DNA immunotherapy candidate
ApolloBio's... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 9,990 | -3,57 % | Wolfe Research stuft Intellia Aktie wegen Bewertungsbedenken herab | ||
| DEFENCE THERAPEUTICS | 0,256 | -5,88 % | Defence Therapeutics Inc.: Defence Therapeutics Opens New Office in Hamilton to Expand Its Accum Radiopharmaceutical Platform | Montreal, Quebec--(Newsfile Corp. - July 8, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| EDITAS MEDICINE | 2,580 | +2,79 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 52,12 | -0,42 % | BioMarin Pharmaceutical Inc.: U.S. Food and Drug Administration Accepts BioMarin's Supplemental New Drug Application for Full Approval of VOXZOGO (vosoritide) for Children With Achondroplasia | Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth... ► Artikel lesen | |
| EXELIXIS | 47,305 | -2,80 % | Will Exelixis (EXEL) Beat Estimates Again in Its Next Earnings Report? | ||
| SAREPTA THERAPEUTICS | 15,000 | -0,40 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| HALOZYME THERAPEUTICS | 67,94 | +0,21 % | Halozyme Therapeutics, Inc.: Halozyme Confirms It Projects Zero to Minimal Impact to Royalty Revenue Through At Least 2035 Based on Newly Released Draft Medicare Drug Price Negotiation Program Proposed Rule for IPAY 2029 | SAN DIEGO, June 15, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today confirmed that the Company expects zero... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,253 | -4,17 % | PacBio to Report Second Quarter 2026 Financial Results on August 5, 2026 | ||
| NEUROCRINE BIOSCIENCES | 150,05 | +0,07 % | Can Neurocrine (NBIX) Run Higher on Rising Earnings Estimates? | ||
| VAXART | 0,600 | 0,00 % | Vaxart, Inc.: Vaxart Announces Results of Annual Meeting of Stockholders |
Das Unternehmen ALX ONCOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,105 Euro und damit +1,69 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.